We first quantified PI3K-related cell signaling pathway activity by exposing live tumor cells derived from four BC patients’ tumor tissue samples (Supplementary Fig. 4a) to PAM inhibitors and evaluating them using the CELsignia PI3K Signaling Pathway test. The gene discussed is PIK3CA; the disease is neoplasm.